LYRA News and Press, Lyra Therapeutics Inc. From 06/16/25

2025-06-16 16:14:20 ET Thesis Overview Lyra therapeutics ( LYRA ) is developing corticosteroid-eluting implants for treatment of chronic rhinosinusitis; LYR-210 for patients without prior surgery and LYR-220 for patients with prior ethmoid sinus surgery. A single therapy (easily...

2025-06-03 10:47:43 ET Lyra Therapeutics, Inc. (NASDAQ: LYRA) is one of today’s top gainers. The company’s shares have moved 30.86% on the day to $26.5. Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of ...

2025-06-02 15:46:11 ET More on Lyra Therapeutics Seeking Alpha’s Quant Rating on Lyra Therapeutics Historical earnings data for Lyra Therapeutics Financial information for Lyra Therapeutics Read the full article on Seeking Alpha For further det...

2025-06-02 10:29:45 ET Lyra Therapeutics, Inc. (NASDAQ: LYRA) is one of today’s top gainers. The company’s shares have moved 451.22% on the day to $27.18. Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization o...

2025-06-02 09:04:39 ET With Expected Second Quarter 2025 closing, Core Gaming Timing Now at a Crossroads DENVER, Colo., Jun 02, 2025 ( 247marketnews.com )- Siyata Mobile’s (NASDAQ:SYTA) $160 million merger with Core Gaming , though a precise closing date remains under...

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in...

Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvements in both symptoms and polyp size ...

2025-05-06 17:13:56 ET More on Lyra Therapeutics Seeking Alpha’s Quant Rating on Lyra Therapeutics Historical earnings data for Lyra Therapeutics Financial information for Lyra Therapeutics Read the full article on Seeking Alpha For further det...

WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS...

Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2025 Standard BioTools Inc. (LAB) is expected to report $-0.06 for Q1 2025 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2025 CF Bankshares Inc. (CFBK) is expected to report for Q1 2025 Jack Henry & A...